An algorithm recommendation for the pharmacological management of allergic rhinitis in Ukraine: a consensus statement from an expert panel
Abstract
Allergic rhinitis (AR) is increasing at an alarming rate in Ukraine. The clinical picture of AR in modern conditions is changing towards more severe and mixed forms. Allergic rhinitis, especially moderate to-severe, has a negative impact on patient quality of life, productivity, direct, and indirect costs. Achieving adequate symptom control is essential for successful AR management, and relies mostly on pharmacotherapy. Most patients use multiple medications to control symptoms faster and better, but symptoms may persist. With the advent of new combination therapies, such as the intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (MP-AzeFlu) like Dymista®, most AR symptoms can be treated effectively. MP-AzeFlu acts synergistically and blocks two important pathophysiological pathways involved in the early- and late-phase reactions of the disease, providing rapid relief from all AR-associated symptoms. A total of 13 experts from Ukraine, Germany, and India participated in the development of this consensus statement. The lead author drafted the questions pertaining to diagnosis, management, treatment adherence, and real-life evidence of AR in Ukraine, and was agreed with the co-authors and expert panel. This consensus is obtained through guiding statements and recommendations based on literature evidences (recent research outcomes, randomized, and comparative studies), clinical practices and personal experience of using MP-AzeFlu in AR by allergist/ immunologists/ otolaryngologists from Ukraine. This consensus statement aimed to assist practitioners in selecting the appropriate treatment strategies, facilitate optimum use of MP-AzeFlu and provide symptomatic relief for patients with AR in the in Ukraine
Downloads
References
Watts AM, Cripps AW, West NP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019; 10: 294. DOI: https://doi.org/10.3389/fphar.2019.00294
Shamji MH, Sharif H, Layhadi JA, Zhu R, Kishore U, Renz H. Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma. J Allergy Clin Immunol. 2022; 149 (3): 791-801. DOI: https://doi.org/10.1016/j.jaci.2022.01.016
World Allergy Association. In-depth review of allergic rhinitis. Available from: https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/in-depth-review-of-allergic-rhinitis; 2020 [Last accessed 30 December 2021]
Puhlik B, Buleza B, Yakovenko O, Chonka Y. The state of allergic service and spread of allergic diseases in Ukraine. Balneo Research Journal. 2013; 4 (1): 46–48. DOI: https://doi.org/10.12680/balneo.2013.1041
Duda L, Okhotnikova O, Sharikadze O et al. Epidemiological characteristics of allergic rhinitis in children in Ukraine. Accessed from: http://eapcongress.com/e-poster///files/DudaLyudmyla_1000.pdf; 2019 [Last accessed 30 December 2021]
Umanets TR, Buratynska AA, Rudnev OO, Lapshyn VF, Antipkin YG. Sensitization profile in children with allergic respiratory diseases. Аsthma and Allergy. 2020; 3: 29–34. DOI: https://doi.org/10.1186/s12948-019-0112-4
Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007; 28 (1): 3–9. DOI: https://doi.org/10.2500/aap.2007.28.2934
Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008; 8 (1): 1–9. DOI: https://doi.org/10.1097/ACI.0b013e3282f3f42f
Ciprandi G, Incorvaia C, Scurati S et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011; 27 (5): 1005–1011. DOI: https://doi.org/10.1185/03007995.2011.559580
Dymista® Summary of product characteristics (SmPC) and patient information leaflet (PIL). Accessed from: https://www.dymista.co.uk/en-gb/hcp/dymista/smpc-and-pil; 2019 [Last accessed 14 December 2021]
Smoke. Fluticasone, combinations. Accessed from: https://mozdocs.kiev.ua/likiview.php?id=38764; 2016 [Last accessed 26 December 2021]
Scadding GK, Kariyawasam HH, Scadding G et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017; 47 (7): 856–889. DOI: https://doi.org/10.1111/cea.12953
Bousquet J, Khaltaev N, Cruz AA et al. World Health Organization; GA(2)LEN; AllerGen. allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 (Suppl 86): 8–160. DOI: https://doi.org/10.1111/j.1398-9995.2007.01620.x
Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011; 1 (3): 157–167. DOI: https://doi.org/10.5415/apallergy.2011.1.3.157
Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018; 14 (Suppl 2): 51. DOI: https://doi.org/10.1186/1710-1492-7-S1-S3
Heinzerling L, Mari A, Bergmann KC et al. The skin prick test - European standards. Clin Transl Allergy. 2013; 3 (1): 3. DOI: https://doi.org/10.1186/2045-7022-3-3
Hellings PW, Scadding G, Bachert C et al. EUFOREA treatment algorithm for allergic rhinitis. Rhinology 2020; 58 (6): 618–622. DOI: https://doi.org/10.4193/Rhin20.246
Scadding GK, Durham SR, Mirakian R et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008; 38 (1): 19–42. DOI: https://doi.org/10.1111/j.1365-2222.2007.02888.x
Gani F, Pozzi E, Crivellaro MA et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy. 2001; 56 (1): 65–68. DOI: https://doi.org/10.1034/j.1398-9995.2001.00794.x
Canonica GW, Triggiani M, Senna G. 360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients. Clin Mol Allergy. 2015; 13: 25.
DOI: https://doi.org/10.1186/s12948-015-0029-5
Sheikh A, Khan-Wasti S, Price D, Smeeth L, Fletcher M, Walker S. Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-center randomized controlled trial. Clin Exp Allergy. 2007; 37 (1): 90–99. DOI: https://doi.org/10.1111/j.1365-2222.2006.02619.x
Matricardi PM, Dramburg S, Alvarez-Perea A et al. The role of mobile health technologies in allergy care: An EAACI position paper. Allergy. 2020; 75 (2): 259–272. DOI: https://doi.org/10.1111/all.13953
Bousquet J, Caimmi DP, Bedbrook A et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. Allergy. 2017; 72 (6): 857–865. DOI: https://doi.org/10.1111/all.13125
Bousquet J, Ansotegui IJ, Anto JM et al. Mobile technology in allergic rhinitis: Evolution in management or revolution in health and care? J Allergy Clin Immunol Pract. 2019; 7 (8): 2511–2523. DOI: https://doi.org/10.1016/j.jaip.2019.07.044
Elliott T, Shih J, Dinakar C, Portnoy J, Fineman S. American college of allergy, asthma & immunology position paper on the use of telemedicine for allergists. Ann Allergy Asthma Immunol. 2017; 119 (6): 512–517. DOI: https://doi.org/10.1016/j.anai.2017.09.052
Tripodi S, Giannone A, Sfika I et al. Digital technologies for an improved management of respiratory allergic diseases: 10 years of clinical studies using an online platform for patients and physicians. Ital J Pediatr. 2020; 46 (1): 105.DOI: https://doi.org/10.1186/s13052-020-00870-z
Florack J, Brighetti MA, Perna S et al. Comparison of six disease severity scores for allergic rhinitis against pollen counts a prospective analysis at population and individual level. Pediatr Allergy Immunol. 2016; 27 (4): 382–390. DOI: https://doi.org/10.1111/pai.12562
Di Fraia M, Tripodi S, Arasi S et al. Adherence to prescribed e-diary recording by patients with seasonal allergic rhinitis: Observational study. J Med Internet Res. 2020; 22 (3): e16642. DOI: https://doi.org/ 10.2196/16642
Bousquet J, Van Cauwenberge P, Bachert C et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003; 58 (3): 192–197. DOI: https://doi.org/10.1034/j.1398-9995.2003.00054.x
Bousquet J, Anto JM, Bachert C et al. Allergic rhinitis. Nat Rev Dis Primers. 2020; 6 (1): 95. DOI: https://doi.org/10.1038/s41572-020-00227-0
Horak F, Zieglmayer UP. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol. 2009; 5 (6): 659–669. DOI: https://doi.org/10.1586/eci.09.38
Kaszuba SM, Baroody FM, deTineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001; 161: 2581–2587. DOI: https://doi.org/10.1001/archinte.161.21.2581
Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140 (4): 950–958. DOI: https://doi.org/10.1016/j.jaci.2017.03.050
Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998; 317 (7173): 1624–1629. DOI: https://doi.org/10.1136/bmj.317.7173.1624
Nielsen LP, Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med. 2003; 2 (1): 55–65. DOI: https://doi.org/10.1007/BF03256639
Erdoğan BA, Sanlı A, Paksoy M, Altın G, Aydın S. Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination. Kulak Burun Bogaz Ihtis Derg. 2014; 24 (4): 217–224. DOI: https://doi.org 10.5606/kbbihtisas.2014.48108
Cingi C, Oghan F, Eskiizmir G, Yaz A, Ural A, Erdogmus N. Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis. Int Forum Allergy Rhinol. 2013; 3 (10): 801–806. DOI: https://doi.org/10.1002/alr.21185
Lipworth B, Newton J, Ram B, Small I, Schwarze J. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27 (1): 3. DOI: https://doi.org/10.1038/s41533-016-0001-y
Ratner PH, Hampel F, Van Bavel J et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100 (1): 74–81. DOI: https://doi.org/10.1016/S1081-1206(10)60408-5
Bjermer L, Westman M, Holmström M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019; 15: 24. DOI: https://doi.org/10.1186/s13223-018-0314-1
D’Addio A, Ruiz N, Mayer M, Murray R, Bachert C. Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity. Clin Transl Allergy. 2015a; 5 (Suppl 4): P40. DOI: https://doi.org/10.1186/2045-7022-5-S4-P40
D’Addio A, Ruiz N, Mayer M, Berger WE, Meltzer EO. Quantification of the distribution of azelastine HCl/fluticasone propionate nasal spray in an anatomical model of the human nasal cavity. J Allergy Clin Immunol. 2015b; 135: AB218. DOI: https://doi.org/10.1016/j.jaci.2014.12.1648
Derendorf H, Munzel U, Petzold U et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012; 74 (1):125–133. DOI: https://doi.org/ 10.1111/j.1365-2125.2012.04222.x
Meltzer EO, Bachert C, Mayer MJ et al. Deposition characteristics of a novel intranasal formulation of azelastine hydrochloride plus fluticasone propionate in an anatomic model of the human nasal cavity. Allergy Asthma Proc. 2020; 41 (4): 265–270. DOI: https://doi.org/10.2500/aap.2020.41.200028
Bousquet J, Schünemann HJ, Hellings PW et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016; 138 (2): 367–374.e2. DOI: https://doi.org/10.1016/j.jaci.2016.03.025
Seidman MD, Gurgel RK, Lin SY et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015; 152 (2): 197–206. DOI: https://doi.org/10.1177/0194599814562166
Bousquet J, Schünemann HJ, Togias A et al. Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020; 145 (1): 70–80.e3. DOI: https://doi.org/10.1016/j.jaci.2019.06.049
Meltzer E, Ratner P, Bachert C et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161 (4): 369–377. DOI: https://doi.org/10.1159/000351404
Hampel FC, Ratner PH, Van Bavel J et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105 (2): 168–173. DOI: https://doi.org/10.1016/j.anai.2010.06.008
Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129 (5): 1282–1289.e10. DOI: https://doi.org/10.1016/j.jaci.2012.01.077
Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012; 33 (4): 324–332. DOI: https://doi.org/10.2500/aap.2012.33.3587
Price D, Shah S, Bhatia S et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013; 23 (7): 495–503.
Bousquet J, Meltzer EO, Couroux P et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018; 6 (5): 1726–1732.e6. DOI: https://doi.org/10.1016/j.jaip.2018.01.031
Dollner R, Lorentz LP, Sheyauldeen S, Kuhl H, Steinsvag S. Real-life effectiveness of a new allergic rhinitis therapy (MP29-02) in Norway. Allergy. 2015; 70 (502). DOI: https://doi.org/10.1186/2045-7022-5-S4-P37
Haahr P, Jacobsen C, Blegvad S, Christensen M, Kuhl H, Nielsen K. Real-life effectiveness of a new allergic rhinitis therapy (MP29-02) in Denmark. Allergy. 2015; 70 (500). DOI: https://doi.org/10.1002/alr.22258
Klimek L, Bachert C, Mosges R et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy Asthma Proc. 2015; 36 (1) :40–47. DOI: https://doi.org/10.2500/aap.2015.36.3823
Stjarne P, Strand V, Theman K, Kuhl H, Ehngage A. Real-life effectiveness of a new allergic rhinitis therapy (MP29-02) in Sweden. Clin Transl Allergy. 2015; 5 (Suppl 4): P37. DOI: https://doi.org/10.1186/2045-7022-5-S4-P37
Klimek L, Bergmann KC, Biedermann T et al. Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017; 26 (1): 16–24. DOI: https://doi.org/10.1007/s40629-016-0006-7
Klimek L, Bachert C, Stjarne P et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. Allergy Asthma Proc. 2016; 37 (5): 376–386. DOI: https://doi.org/10.2500/aap.2016.37.3979
Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immun Inflamm Dis. 2018; 6 (4): 456–464. DOI: https://doi.org/10.1002/iid3.237
Price D, Klimek L, Gálffy G et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clin Mol Allergy. 2020; 18: 15. DOI: https://doi.org/10.1186/s12948-020-00130-9
Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018; 39 (2): 110–106. DOI: https://doi.org/10.2500/aap.2018.39.4116
Price D, Bousquet J, Hellings P et al. Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis. Clin Transl Allergy. 2013; 3 (Suppl 2): O15. DOI: https://doi.org/10.1517/14740338.2016.1122755
Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother. 2012; 8 (10):1499–1512. DOI: https://doi.org/10.4161/hv.21629
Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. Drug Discov Today. 2016; 21 (1): 26–37. DOI: https://doi.org/10.1016/j.drudis.2015.07.010
Alvaro-Lozano M, Akdis CA, Akdis M et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol. 2020; 31 (Suppl 25): 1–101. DOI: https://doi.org/10.1111/pai.13189
Campisi L, Yong PFK, Kasternow B, Karim MY. Illustrative case series and narrative review of therapeutic failure of immunotherapy for allergic rhinitis. Allergy Rhinol (Providence). 2020; 11: 2152656720943822. DOI: https://doi.org/10.1177/2152656720943822
Chhabra N, Houser SM. Surgical options for the allergic rhinitis patient. Curr Opin Otolaryngol Head Neck Surg. 2012; 20 (3): 199–204. DOI: https://doi.org/10.1097/MOO.0b013e328352b821
Karatzanis AD, Fragiadakis G, Moshandrea J, Zenk J, Iro H, Velegrakis GA. Septoplasty outcome in patients with and without allergic rhinitis. Rhinology. 2009; 47 (4): 444–449. DOI: https://doi.org/10.4193/Rhin08.126
Ivanovich KA, Bondareva GP, Thao NPT. Allergic rhinitis complicated by hypertrophy of the mucous membrane of nasal turbinates in patients of Northern Vietnam. Biomedical Research and Therapy. 2020; 7: 3813–3818. DOI: https://doi.org/10.15419/bmrat.v7i6.609
Scadding G, Price D, El-Shanawany T, Ahmed S, Ray J, Sargur R, Kumar N. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017; 7 (4): e014777. DOI: https://doi.org/10.1136/bmjopen-2016-014777
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
